恒瑞医药(600276.SH)：SHR-3045注射液获得药物临床试验批准通知书

Core Insights - Company subsidiary Guangdong Hengrui Medicine Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. received approval from the National Medical Products Administration for the clinical trial of SHR-3045 injection [1] - SHR-3045 injection is a self-developed biological product aimed at treating rheumatoid arthritis, expected to suppress immune cell function, reduce inflammation, and improve clinical symptoms [1] Company Developments - The clinical trial for SHR-3045 injection will commence shortly following the approval [1] - This development highlights the company's ongoing commitment to advancing its pipeline of innovative treatments in the biopharmaceutical sector [1]